Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Rule 8.3-Angle Plc

12 May 2008 13:20

RNS Number : 2093U
Kaupthing Bank hf
12 May 2008
 
FORM 8.3
DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE
(Rule 8.3 of the Takeover Code)
 
 
1. KEY INFORMATION
 
Name of person dealing (Note 1)
Kaupthing Bank hf
Company dealt in
Angle Plc
Class of relevant security to which the dealings being disclosed relate(Note 2)
Ordinary Shares
Date of dealing
09 May 2008
 
 
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
 
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
 
 
 
Long
Short
 
 
Number (%)
Number (%)
(1) Relevant securities
 
 
9,418 (0.03%)
(2) Derivatives (other than options)
 
1,017,125 (3.75 %)
 
1,017,125 (3.75 %)
 
(3) Options and agreements to purchase/sell
 
 
 
Total
 
1,017,707 (3.75 %)
 
1,026,543 (3.78 %)
 
 
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
 
Class of relevant security:
 
Long
Short
 
 
Number (%)
Number (%)
(1) Relevant securities
 
 
 
(2) Derivatives (other than options)
 
 
 
(3) Options and agreements to purchase/sell
 
 
 
Total
 
 
 
 
(c) Rights to subscribe (Note 3)
 
Class of relevant security:
 
Details
 
 
 
 
 
3. DEALINGS (Note 4)
 
(a) Purchases and sales 
 
Purchase/sale
 
Number of securities
Price per unit (Note 5)
Sell
10,000
39.50p
 
 
 
 (b) Derivatives transactions (other than options)
 
Product name,
e.g. CFD
Long/short (Note 6)
Number of securities (Note 7)
Price per unit (Note 5)
 
 
 
 
 
 
 
 
 
 
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
 
Product name,
e.g. call option
 
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise
price
Type, e.g. American, European etc.
Expiry
date
Option money
paid/received per unit (Note 5)
 
 
 
 
 
 
 
 
 
 
 
 
(ii) Exercising
 
Product name, e.g. call option
Number of securities
Exercise price per unit (Note 5)
 
 
 
 
 
 
(d) Other dealings (including new securities) (Note 4)
 
Nature of transaction (Note 8)
 
Details
Price per unit (if applicable)(Note 5)
 
 
 
 
 
 
4. OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. 
No voting rights on CFD holdings
 
 
 
Is a Supplemental Form 8 attached? (Note 9) NO
 
 
Date of disclosure
12 May 2008
Contact name
Richard Easton
Telephone number
0203 205 6620
If a connected EFM, name of offeree/offeror with which connected
 
If a connected EFM, state nature of connection (Note 10)
 
 
 
Notes
 
The Notes on Form 8.3 can be viewed on the Takeover Panel’s website at www.thetakeoverpanel.org.uk
 
 
This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETXLLFFVEBFBBD
Date   Source Headline
3rd Jun 20157:00 amRNSAppointment of Scientific Adviser
26th May 20157:01 amRNSNew Patent Grants
21st Apr 20157:00 amRNSOvarian Cancer Update
20th Apr 20157:00 amRNSSidney Kimmel Cancer Centre
14th Apr 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSOffer to Shareholders
25th Feb 20151:11 pmRNSIssue of Equity
20th Feb 20154:05 pmRNSHolding(s) in Company
16th Feb 20157:01 amRNSMD Anderson Collaboration
16th Feb 20157:00 amRNSPlacing, Subscription and Offer
29th Jan 20157:00 amRNSInterim Results
27th Jan 20157:01 amRNS"Unprecedented Specificity" in Ovarian Cancer
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
21st Jan 20153:00 pmRNSFurther information re Director's share transfer
19th Jan 20157:00 amRNSNotification of Interim Results
8th Jan 20157:00 amRNSCorporate Collaboration
15th Dec 20147:00 amRNSCancer Research Manchester Institute Publication
12th Nov 20147:00 amRNSFurther information re Director's share transfer
10th Nov 20147:00 amRNSIssue of Share Options
31st Oct 20147:00 amRNSADR PROGRAMME
21st Oct 20147:00 amRNSDirector's Share Transfer
17th Oct 20147:00 amRNSKey Opinion Leaders Report on Parsortix System
17th Oct 20147:00 amRNSCollaboration with Barts Cancer Institute
30th Sep 20144:30 pmRNSResult of AGM
30th Sep 20147:00 amRNSCollaboration with Thomas Jefferson University
25th Sep 20147:00 amRNSADR Programme, FDA Update and US Appointment
19th Sep 20147:00 amRNSBreast Cancer Collaboration
17th Sep 20147:00 amRNSCollaboration with Medical University of Vienna
8th Sep 20147:00 amRNSHamburg-Eppendorf Collaboration
4th Aug 20147:00 amRNSParsortix Granted Second US Patent
23rd Jul 20147:00 amRNSPreliminary Results
22nd Jul 20147:00 amRNSParsortix Evaluation
1st Jul 20147:00 amRNSNotification of Preliminary Results
29th Apr 20144:30 pmRNSHoldings in Company
8th Apr 20147:00 amRNSIntellectual Property Update
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.